Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EYP-1901 versus aflibercept in wet AMD
NCT05381948Phase 2Completed
- Sponsor
- EyePoint Pharmaceuticals
- Start
- Jun 2022
- Primary completion
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of vorolanib in exudative macular degeneration (3 arms), sponsored by EyePoint Pharmaceuticals. Primary endpoint: Best Corrected Visual Acuity at 32 weeks. Started Jun 2022; status: completed.
02
Drugs
vorolanib
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on NCT05381948.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05381948.